Navigation Links
New England Biolabs Introduces OneTaq™ DNA Polymerase, a Robust Solution for Routine and Difficult PCR
Date:2/14/2011

IPSWICH, Mass., Feb. 14, 2011 /PRNewswire/ -- New England Biolabs has expanded its line of PCR reagents to include OneTaq™ and OneTaq Hot Start DNA Polymerases. Optimized blends of Taq and Deep Vent® DNA Polymerases, these new products offer robust amplification across a wide range of templates, including routine, AT-rich and GC-rich amplicons. The 3´–5´ exonuclease activity of Deep Vent increases the fidelity and robustness of Taq, while the optimized buffers further enhance yield and product purity, regardless of a template's GC content.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b)

In addition, OneTaq Hot Start DNA Polymerase utilizes aptamer technology; NEB's unique aptamer blocks polymerase activity at temperatures below 45 degrees C, and the polymerase is activated during normal cycling conditions. Available in convenient product formats, including master mixes, OneTaq shows exceptional performance against other commercially available polymerases, especially when amplifying difficult or GC-rich templates.

As part of its commitment to customer service and product excellence, NEB is inviting researchers to sample OneTaq and OneTaq Hot Start, submit comments with data, and earn a chance to win a free iPad®. NEB will use the feedback to aid in the development of future PCR reagent offerings.

"OneTaq DNA Polymerase represents a powerful solution to the vast majority of endpoint PCR needs," states Dr. Fiona Stewart, Product Marketing Manager for New England Biolabs. "Additionally, OneTaq Hot Start offers the convenience of setting up reactions at room temperature without a separate activation step."

OneTaq and OneTaq Hot Start samples can be requested online at www.neb.com/OneTaq . For more information on contest rules, please visit www.neb.com/onetaqcontest .

About NEB

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications, and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs, visit www.neb.com.

iPad® is a registered trademark of Apple Computer, Inc.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The New England Journal of Medicine Publishes Results of Fidaxomicin Phase 3 Trial Showing Significantly Lower Recurrence Rates and Improved Global Cure Rates Compared to Vancomycin in Patients with Clostridium difficile Infection (CDI)
2. New England Biolabs Develops Novel Small RNA NGS Protocol: Reagents Improve Yield and Decrease Adaptor-Dimer Formation
3. CSL Behring Awards Advocacy Grants to Patient Groups in Maryland, New England, the Midwest and Washington
4. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
5. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
6. New England Biolabs Launches NEBNext(TM) DNA Sample Prep Master Mix Set 3 for Use with SOLiD(TM) 3
7. Wellcome Trust Sanger Institute to use NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for Next Generation Sequencing
8. Organogenesis CEO Geoff MacKay and COO / CFO Gary Gillheeney Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winners in New England
9. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
10. First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009
11. Data Published in The New England Journal of Medicine Support Use of Raxibacumab (ABthrax(TM)) for the Treatment of Inhalation Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/23/2017)... DIEGO and SAN FRANCISCO ... a privately-held regenerative medicine company, and Beyond Type 1, ... with type 1 diabetes, today announced a grant from ... a functional cure for type 1 and other insulin-requiring ... ViaCyte has been developing innovative stem cell-derived cell replacement ...
(Date:2/22/2017)...  Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company ... products for companion animals, will host a live conference call ... discuss financial results from the fourth quarter and full year ... investors may access the audio webcast or use ... ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , a leader in Atomic ... all SPIE attendees and Park customers on Feb. 27, 2017 from 12-2pm ... Jose Convention Center. The luncheon will feature a talk on Automated AFM for ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
Breaking Biology News(10 mins):